This webinar has been postponed. If you’d like to be added to the rescheduled session, please reach out to [email protected].
Regulatory strategy is no longer a downstream consideration—it’s a defining driver of development timelines, investor confidence, and long-term asset value. In today’s environment, increasing regulatory complexity, evolving FDA expectations, and more rigorous investor scrutiny mean early decisions can be game-changing. Missteps—whether in CMC strategy, cross-functional alignment, or early development design—tend to compound, leading to delays, added cost, and missed partnership opportunities.
In this Ask Me Anything session, we’ll take a practical, experience-based look at how regulatory strategy shapes development outcomes, grounded in real-world program examples.
Topics will include:
- How early CMC shortcuts often translate into technical debt later in development
- The impact of misaligned clinical, nonclinical, and CMC narratives on regulatory credibility
- How early design decisions can constrain scalability and limit future deal potential
We’ll also discuss what high-performing teams do differently—approaches to strengthening cross-functional alignment, identifying risks earlier, and building a more cohesive regulatory narrative from the start.
Attendees will leave with a clearer view of how to proactively manage regulatory risk—and how to position programs for stronger performance across development, approval, and partnership milestones.
